Clinical Trial

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Protocol Amendment History 2 changes
notable Trial sites expanded: 20 -> 23 locations 2026-04-23
notable Trial sites expanded: 12 -> 20 locations 2026-04-16
Trial Details
NCT Number NCT07222267
Lead Sponsor BeOne Medicines
Conditions Breast Cancer, Advanced Solid Tumor
Enrollment 86 participants
Start Date 2025-12-11
Primary Completion 2029-09-30 (estimated)
Study Completion 2037-01-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-14